Research programme: anti-messenger RNA vectors - Engevity

Drug Profile

Research programme: anti-messenger RNA vectors - Engevity

Alternative Names: Vigilant vector

Latest Information Update: 02 Apr 2007

Price : $50

At a glance

  • Originator University of Florida
  • Developer Engevity
  • Class
  • Mechanism of Action RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Myocardial infarction

Most Recent Events

  • 15 Apr 2003 Preclinical trials in Myocardial infarction in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top